Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Chinese Patent Office
QuintilesIMS
Accenture
McKesson
Cipla
Argus Health
Express Scripts
US Department of Justice

Generated: May 27, 2018

DrugPatentWatch Database Preview

MITIGARE Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Mitigare patents expire, and what generic alternatives are available?

Mitigare is a drug marketed by Hikma Intl Pharms and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in MITIGARE is colchicine. There are sixteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the colchicine profile page.
Summary for MITIGARE
US Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: 4
Bulk Api Vendors: 67
Formulation / Manufacturing:see details
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for MITIGARE
DailyMed Link:MITIGARE at DailyMed
Drug patent expirations by year for MITIGARE
Pharmacology for MITIGARE
Mechanism of ActionCytochrome P450 3A4 Inhibitors
P-Glycoprotein Interactions
Medical Subject Heading (MeSH) Categories for MITIGARE
Gout Suppressants
Tubulin Modulators

US Patents and Regulatory Information for MITIGARE

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hikma Intl Pharms MITIGARE colchicine CAPSULE;ORAL 204820-001 Sep 26, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Hikma Intl Pharms MITIGARE colchicine CAPSULE;ORAL 204820-001 Sep 26, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Hikma Intl Pharms MITIGARE colchicine CAPSULE;ORAL 204820-001 Sep 26, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Hikma Intl Pharms MITIGARE colchicine CAPSULE;ORAL 204820-001 Sep 26, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for MITIGARE
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Capsules 0.6 mg ➤ Subscribe 2016-06-10

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Cerilliant
McKinsey
US Army
Baxter
Covington
UBS
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
DrugPatentWatch reviews  
Links

Follow DrugPatentWatch: